Among patients with COPD and type 2 inflammation at an urgent outpatient visit, the ED or hospital, a single dose of add-on rademikibart vs. placebo lowered treatment failure through 4 weeks, ...

A single injection of the next-generation drug rademikibart markedly cut the rate and impact of acute exacerbations among ...

AstraZeneca’s tozorakimab reduced disease flare ups in patients with COPD, suggesting IL-33-targeted antibodies could offer broad potential in pulmonary diseases.

Breathing exercises remain an underused, safe, low-cost therapy for COPD — and new research shows a humor-infused technique ...

The main French supermarket chains were hit today by a cyberattack that rendered refrigerators and freezers in hundreds of stores unusable, thus forcing the disposal of fresh and frozen food worth ...

A new experimental drug called CS18 may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment. It strengthened existing therapies, restored ...

Early results have been striking. In a phase 2 trial, participants taking the highest dose lost nearly one-quarter of their body weight in less than a year. Researchers continue to study its safety, ...

(Adnkronos) - "Are Atp Finals tickets selling without Sinner? I'm sorry to disappoint you, you'll see the numbers, beyond the great disappointment for our world champion, the Nitto Atp Finals are ...

Novo Nordisk NOVO.B2.14%increase; up pointing triangle Chief Executive Mike Doustdar, who took over in 2025 promising to find a sustainable growth path, said the company will launch several new ...

Replicate phase 3 trials show the IL-33-targeting monoclonal antibody reduces moderate and severe exacerbations regardless of blood eosinophil levels or smoking status.

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. The FDA has approved Rasonque (daraxonrasib) as a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...